Novel vaccine safe, effective in ovarian cancer subset


Sumary of Novel vaccine safe, effective in ovarian cancer subset:

  • A novel vaccine appeared safe and demonstrated clinical benefit as front-line maintenance therapy for women with advanced-stage ovarian cancer, according to results of a phase 2b trial presented during the virtual ASCO Annual Meeting..
  • Gemogenovatucel-T (Gradalis Inc.) showed benefit among women with BRCA wild-type and homologous recombination-proficient ovarian cancer..
  • “It is well-known that cancer immunology involves transmitting anti-immune signals to undergo an immune escape..
  • Gemogenovatucel-T is an autologous tumor DNA immunotherapy derived from patients’ cancer cells at the time of surgery,”.
  • Rocconi, MD, chief of the gynecologic oncology service, associate director for clinical research and professor of interdisciplinary clinical oncology at University of South Alabama Mitchell Cancer Institute, said during his presentation..
  • This collectively results in production of a cancer neoantigen-specific immune response that is patient-specific, where each vaccine is only good for a specific patient cancer.”.
  • For the double-blind, placebo-controlled VITAL trial, researchers enrolled 91 women with newly diagnosed advanced-stage ovarian cancer who had a complete clinical response to front-line surgery and chemotherapy..
  • They used the Myriad myChoice CDx (Myriad Genetics) assay to determine women homologous recombination deficiency status, with scores of less than 42 deemed proficient….

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.